Jane Chung's most recent trade in Sutro Biopharma Inc was a trade of 788 Common Stock done . Disclosure was reported to the exchange on March 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2026 | 788 | 21,567 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2026 | 788 | 0 | - | - | Restricted Stock Units (RSUs) | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.31 per share. | 04 Mar 2026 | 282 | 21,285 (0%) | 0% | 21.3 | 6,009 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2026 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2026 | 40,000 | 40,000 | - | - | Restricted Stock Units (RSUs) | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 7,750 | 23,558 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 7,750 | 23,250 | - | - | Restricted Stock Units (RSUs) | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.55 per share. | 01 Mar 2026 | 2,779 | 20,779 (0%) | 0% | 20.5 | 57,108 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 2,500 | 17,079 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 2,500 | 5,000 | - | - | Restricted Stock Units (RSUs) | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.47 per share. | 01 Mar 2026 | 1,271 | 15,808 (0%) | 0% | 20.5 | 26,017 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 688 | 14,579 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 688 | 688 | - | - | Restricted Stock Units (RSUs) | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 2,500 | 5,000 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 2,500 | 14,785 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.01 per share. | 12 Dec 2025 | 894 | 13,891 (0%) | 0% | 8.0 | 7,165 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.80 per share. | 15 Oct 2025 | 12,500 | 122,850 (0%) | 0% | 0.8 | 10,011 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2025 | 18,750 | 117,058 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2025 | 18,750 | 0 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.80 per share. | 09 Aug 2025 | 6,708 | 110,350 (0%) | 0% | 0.8 | 5,366 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2025 | 620,000 | 620,000 | - | - | Stock Option (Right to Buy) | |
| Sutro Biopharma Inc | Jane Chung | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2025 | 310,000 | 310,000 | - | - | Restricted Stock Units (RSUs) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 7,875 | 100,642 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 7,875 | 7,875 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.42 per share. | 04 Mar 2025 | 2,334 | 98,308 (0%) | 0% | 1.4 | 3,314 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 25,000 | 75,000 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 25,000 | 102,217 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.59 per share. | 01 Mar 2025 | 9,450 | 92,767 (0%) | 0% | 1.6 | 15,026 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 6,875 | 13,750 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 6,875 | 77,217 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Chung Jane | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 25,000 | 79,262 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 25,000 | 75,000 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 01 Dec 2024 | 8,920 | 70,342 (0%) | 0% | 2.7 | 23,995 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2024 | 18,750 | 60,951 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2024 | 18,750 | 18,750 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.12 per share. | 09 Aug 2024 | 6,689 | 54,262 (0%) | 0% | 3.1 | 20,870 | Common Stock |
| Viracta Therapeutics Inc | Jane Chung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 100,000 | 100,000 | - | - | Restricted Stock Units (RSUs) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy Common Stock) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 7,875 | 15,750 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 7,875 | 44,410 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.79 per share. | 04 Mar 2024 | 2,209 | 42,201 (0%) | 0% | 4.8 | 10,581 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 6,875 | 38,573 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 6,875 | 20,625 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.95 per share. | 01 Mar 2024 | 2,038 | 36,535 (0%) | 0% | 4.9 | 10,088 | Common Stock |
| Sutro Biopharma Inc | Chung Jane | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 100,000 | 100,000 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2023 | 18,750 | 37,500 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2023 | 18,750 | 38,181 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.22 per share. | 09 Aug 2023 | 6,483 | 31,698 (0%) | 0% | 4.2 | 27,358 | Common Stock |
| Viracta Therapeutics Inc | Jane Chung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 27,500 | 27,500 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 7,875 | 23,625 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 7,875 | 22,642 (0%) | 0% | - | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.79 per share. | 03 Mar 2023 | 3,211 | 19,431 (0%) | 0% | 5.8 | 18,592 | Common Stock |
| Viracta Therapeutics Inc | Jane Chung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2022 | 18,750 | 56,250 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2022 | 18,750 | 21,250 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.60 per share. | 09 Aug 2022 | 6,483 | 14,767 (0%) | 0% | 6.6 | 42,788 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 42,000 | 42,000 | - | - | Stock Option (right to buy) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 31,500 | 31,500 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2021 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2021 | 75,000 | 75,000 | - | - | Restricted Stock Unit (RSU) |